Last $5.25 USD
Change Today 0.00 / 0.00%
Volume 21.3K
ALQA On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

alliqua inc (ALQA) Snapshot

Open
$5.37
Previous Close
$5.25
Day High
$5.41
Day Low
$5.20
52 Week High
01/16/14 - $10.11
52 Week Low
10/15/13 - $2.63
Market Cap
82.6M
Average Volume 10 Days
37.8K
EPS TTM
$-2.71
Shares Outstanding
15.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALLIQUA INC (ALQA)

Related News

No related news articles were found.

alliqua inc (ALQA) Related Businessweek News

No Related Businessweek News Found

alliqua inc (ALQA) Details

Alliqua, Inc. develops, manufactures, and markets proprietary transdermal wound care and drug delivery technologies. The company provides water content, electron beam cross-linked, and aqueous polymer hydrogels for use in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Its products include SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. The company also develops HepaMate, an extracorporeal temporary liver support system designed to provide whole liver function to patients with acute or severe liver failure. It has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. The company was formerly known as AquaMed Technologies, Inc. and changed its name to Alliqua, Inc. in May, 2010. Alliqua, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

21 Employees
Last Reported Date: 03/24/14
Founded in 2009

alliqua inc (ALQA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $483.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $96.7K
Compensation as of Fiscal Year 2013.

alliqua inc (ALQA) Key Developments

Alliqua BioMedical, Inc. Announces Board Changes

Alliqua BioMedical, Inc. announced the appointment of Andrew Africk and Gary Restani to its board of directors. The company also announced the departure of David Stefansky and Kenneth D. Pearson from its board of directors. Mr. Africk recently formed Searay Capital LLC after 21 years successfully leading private equity and capital markets investments for Apollo Global Management LLC. Mr. Africk currently serves on the Board of Overseers of the University of Pennsylvania School of Engineering, the UCLA Science Board, and is a Trustee of the Trinity School in New York City. Mr. Restani currently serves as Vice Chairman on the board of directors for Spiracur Inc.

Alliqua, Inc. has Changed its Name to Alliqua BioMedical, Inc

On June 06, 2014, Alliqua, Inc. changed its name to Alliqua BioMedical, Inc.

Alliqua, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014

Alliqua, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2014. Revenues for the first quarter of 2014 were approximately $591,000, an increase of 51% compared to first quarter 2013 revenues of approximately $392,000. This increase was largely due to an increase in revenues of the company's proprietary and licensed products of approximately $106,000 compared to the first quarter of 2013. The operating loss for the three months ended March 31, 2014 was approximately $8.8 million, as compared to approximately $2.1 million for the prior year period. Contributing to this increase in net operating loss were non-cash stock-based compensation and cash salary compensation and benefits which increased by approximately $4.2 million and $1.4 million, respectively, compared to the first quarter of 2013. Included in these costs are compensation and benefits and stock-based compensation expense for former employees of approximately $1.2 million. Loss before income tax provision was $9,032,662 against $2,700,835 a year ago. Net loss was $9,036,162 aganst $2,703,835 a year ago. Basic and diluted net loss per common share was $0.73 against $0.45 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQA:US $5.25 USD 0.00

ALQA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr475.00 DKK -2.50
Covidien PLC $89.10 USD -0.19
Derma Sciences Inc $9.87 USD -0.20
Smith & Nephew PLC 1,062 GBp -4.00
View Industry Companies
 

Industry Analysis

ALQA

Industry Average

Valuation ALQA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.5x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLIQUA INC, please visit alliqua.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.